

# Alessandro Consolaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2425873/publications.pdf>

Version: 2024-02-01

137  
papers

3,695  
citations

126907

33  
h-index

138484

58  
g-index

139  
all docs

139  
docs citations

139  
times ranked

2917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 658-666.	6.7	579
2	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213030.	0.9	183
3	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. <i>Arthritis and Rheumatism</i> , 2012, 64, 2366-2374.	6.7	171
4	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. <i>Journal of Rheumatology</i> , 2011, 38, 938-953.	2.0	159
5	Juvenile Idiopathic Arthritis: Diagnosis and Treatment. <i>Rheumatology and Therapy</i> , 2016, 3, 187-207.	2.3	148
6	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 764-768.	2.0	140
7	Clinical outcome measures in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2016, 14, 23.	2.1	133
8	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	5.6	120
9	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1534-1541.	2.0	119
10	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score. <i>Arthritis Care and Research</i> , 2014, 66, 1703-1709.	3.4	115
11	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1083-1090.	0.9	113
12	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	5.6	101
13	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1380-1383.	0.9	77
14	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. <i>Rheumatology International</i> , 2018, 38, 5-17.	3.0	74
15	Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 856-863.	2.0	72
16	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. <i>Arthritis Research and Therapy</i> , 2018, 20, 285.	3.5	71
17	Seeking insights into the Epidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. <i>Pediatric Rheumatology</i> , 2012, 10, 39.	2.1	70
18	TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 435-441.	0.9	64

#	ARTICLE	IF	CITATIONS
19	Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2011, 50, 1627-1634.	1.9	59
20	Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). <i>Arthritis Care and Research</i> , 2011, 63, S112-7.	3.4	55
21	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. <i>Lancet, The</i> , 2017, 389, 909-916.	13.7	52
22	Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. <i>Journal of Rheumatology</i> , 2013, 40, 192-200.	2.0	43
23	Prevalence of Overweight and Obesity in 6-year-old Italian Children. <i>Obesity</i> , 2006, 14, 765-769.	3.0	42
24	Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 416-421.	2.0	41
25	Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 183-190.	2.0	40
26	Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children. <i>European Journal of Endocrinology</i> , 2006, 154, 61-68.	3.7	39
27	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016, 7, 467.	3.5	39
28	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020, 59, 3505-3514.	1.9	39
29	Delineating the Role of Multiple Intraarticular Corticosteroid Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era. <i>Arthritis Care and Research</i> , 2013, 65, 1112-1120.	3.4	38
30	Advances in biomarkers for paediatric rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 265-275.	8.0	37
31	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. <i>Arthritis Research and Therapy</i> , 2019, 21, 168.	3.5	37
32	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 363-368.	0.9	36
33	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. <i>Pediatric Rheumatology</i> , 2016, 14, 68.	2.1	35
34	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	2.0	34
35	Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S157-62.	0.8	34
36	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1966-1975.	5.6	33

#	ARTICLE	IF	CITATIONS
37	Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1773-6.	2.0	30
38	The conundrum of juvenile psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S40-3.	0.8	28
39	Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 1262-1270.	3.4	27
40	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1416-1425.	2.0	25
41	Defining criteria for disease activity states in juvenile idiopathic arthritis: Table 1. <i>Rheumatology</i> , 2016, 55, 595-596.	1.9	22
42	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. <i>Arthritis Care and Research</i> , 2018, 70, 1312-1319.	3.4	19
43	Unraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas – Key to Understanding Etiology and Genetic Factors?. <i>Journal of Rheumatology</i> , 2016, 43, 683-685.	2.0	15
44	Glucocorticoids in Juvenile Idiopathic Arthritis. <i>NeuroImmunoModulation</i> , 2015, 22, 112-118.	1.8	13
45	Juvenile idiopathic arthritis – are biologic agents effective for pain?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 447-448.	8.0	12
46	Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. <i>Current Rheumatology Reports</i> , 2016, 18, 8.	4.7	12
47	A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1540-1550.	5.6	11
48	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1884-1888.	2.0	11
49	Molecular mechanisms of autophagic memory in pathogenic T cells in human arthritis. <i>Journal of Autoimmunity</i> , 2018, 94, 90-98.	6.5	11
50	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. <i>Rheumatology</i> , 2019, 58, 1196-1205.	1.9	10
51	Neutrophil Extracellular Traps in Systemic Lupus Erythematosus Stimulate IgG2 Production From B Lymphocytes. <i>Frontiers in Medicine</i> , 2021, 8, 635436.	2.6	10
52	Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 853-870.	3.0	10
53	Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S98-101; quiz S102-7.	0.8	10
54	It Is Worth Including Assessment of Disease Activity State in Juvenile Arthritis Clinical Trials. <i>Arthritis Care and Research</i> , 2013, 65, 1207-1210.	3.4	9

#	ARTICLE	IF	CITATIONS
55	Recent therapeutic advances in juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 476-487.	3.3	9
56	The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 43-49.	3.0	8
57	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 35-42.	3.0	8
58	The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 267-274.	3.0	8
59	Treating Juvenile Idiopathic Arthritis According to JADAS-Based Targets. <i>Annals of Paediatric Rheumatology</i> , 2014, 3, 4.	0.0	8
60	Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 964-8.	0.8	8
61	The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 75-82.	3.0	7
62	Recent advances in quantitative assessment of juvenile idiopathic arthritis. <i>Annals of Paediatric Rheumatology</i> , 2012, 1, 84.	0.0	7
63	Cardiovascular Manifestations in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 According to Age. <i>Children</i> , 2022, 9, 583.	1.5	7
64	Preface. <i>Rheumatology International</i> , 2018, 38, 1-3.	3.0	6
65	The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 155-161.	3.0	6
66	Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 3-5.	2.0	5
67	The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 403-409.	3.0	5
68	The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 299-306.	3.0	5
69	A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019, 17, 50.	2.1	5
70	Outcome Scores in Pediatric Rheumatology. <i>Current Rheumatology Reports</i> , 2021, 23, 23.	4.7	5
71	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 395-402.	3.0	4
72	The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 27-33.	3.0	4

#	ARTICLE	IF	CITATIONS
73	A child with a novel ACAN missense variant mimicking a septic arthritis. Italian Journal of Pediatrics, 2019, 45, 148.	2.6	4
74	The Effect of Morning Stiffness Duration on the Definition of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2020, 47, 1238-1241.	2.0	4
75	Outcome Measures for Juvenile Idiopathic Arthritis Disease Activity. Arthritis Care and Research, 2020, 72, 150-162.	3.4	4
76	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 898-906.	2.0	4
77	Information technology in paediatric rheumatology. Clinical and Experimental Rheumatology, 2016, 34, S11-S16.	0.8	4
78	The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 67-73.	3.0	3
79	Treat to Target in Juvenile Idiopathic Arthritis: Challenges and Opportunities. Current Treatment Options in Rheumatology, 2018, 4, 29-43.	1.4	3
80	Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arthritis. Arthritis Care and Research, 2020, 73, 1722-1729.	3.4	3
81	Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis. RMD Open, 2022, 8, e002042.	3.8	3
82	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	3.0	2
83	The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 19-26.	3.0	2
84	The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 211-218.	3.0	2
85	The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 139-146.	3.0	2
86	Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring. Arthritis Care and Research, 2022, , .	3.4	2
87	Section 4: Juvenile Idiopathic Arthritis. Clinical Drug Investigation, 2013, 33, 133-137.	2.2	1
88	Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries. Pediatric Rheumatology, 2014, 12, .	2.1	1
89	A30: Assessment of Construct and Discriminative Validity of the 3-Variable JADAS in Relation of Parent-Reported Outcomes. Arthritis and Rheumatology, 2014, 66, S46-S46.	5.6	1
90	The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 235-242.	3.0	1

#	ARTICLE	IF	CITATIONS
91	The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 387-393.	3.0	1
92	The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 243-250.	3.0	1
93	The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 83-90.	3.0	1
94	The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 219-226.	3.0	1
95	The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 171-178.	3.0	1
96	FRI0547â€¦DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
97	Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
98	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	2.1	0
99	Trial Design and Collaborative Work in Pediatric Rheumatology. , 2017, , 47-54.		0
100	The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 59-66.	3.0	0
101	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 51-58.	3.0	0
102	The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 227-233.	3.0	0
103	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 363-369.	3.0	0
104	The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 107-113.	3.0	0
105	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 283-289.	3.0	0
106	The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 99-105.	3.0	0
107	The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 275-282.	3.0	0
108	The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 347-354.	3.0	0

#	ARTICLE	IF	CITATIONS
109	The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 371-377.	3.0	0
110	The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 187-194.	3.0	0
111	The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 115-122.	3.0	0
112	The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 147-153.	3.0	0
113	The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 179-186.	3.0	0
114	The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 291-298.	3.0	0
115	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 307-313.	3.0	0
116	The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 315-321.	3.0	0
117	The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 331-338.	3.0	0
118	The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 91-98.	3.0	0
119	The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 131-138.	3.0	0
120	The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 163-169.	3.0	0
121	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	3.0	0
122	The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 203-209.	3.0	0
123	The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 259-265.	3.0	0
124	The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 355-361.	3.0	0
125	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	3.0	0
126	The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 323-329.	3.0	0

#	ARTICLE	IF	CITATIONS
127	The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 123-130.	3.0	0
128	The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 339-346.	3.0	0
129	AB1316â€¦.AGREEMENT BETWEEN SUBJECTIVE AND OBJECTIVE DEFINITIONS OF INACTIVE DISEASE IN CHILDREN WITH JUVENILE IDIOPATHIC ARHRITIS. , 2019, , .		0
130	SAT0024â€¦.TRANSCRIPTOMIC PROFILING OF THE MICROENVIRONMENT DRIVEN RE-SHAPING OF PATHOGENIC CIRCULATORY AND SYNOVIAL HLA-DR+ CD4 T SUBSETS IN ACTIVE JUVENILE IDIOPATHIC ARTHRITIC PATIENTS. , 2019, , .		0
131	FRI0571â€¦.MEASUREMENT PERFORMANCE OF REDUCED VERSIONS OF MUSCLE STRENGTH TOOLS IN JUVENILE DERMATOMYOSITIS. , 2019, , .		0
132	THU0655â€¦.LONG-TERM OUTCOME OF JUVENILE IDIOPATHIC ARTHRITIS: COMPARISON OF BIOLOGIC AND METHOTREXATE ERAS. , 2019, , .		0
133	THU0515â€¦.PAIN IS THE MAIN DETERMINANT OF WELL-BEING IN OLIGO- AND POLYARTICULAR JIA: EVIDENCE FROM THE PHARMACHILD REGISTRY. , 2019, , .		0
134	SAT0501â€¦.THE IMPACT OF MORNING STIFFNESS ON THE DEFINITION OF INACTIVE DISEASE IN JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
135	THU0594â€¦.CLINICAL VERSUS IMAGING REMISSION IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): PRELIMINARY RESULTS OF THE REMECO STUDY. , 2019, , .		0
136	Outcome Measures in Pediatric Rheumatic Disease. Rheumatic Disease Clinics of North America, 2021, 47, 655-668.	1.9	0
137	Biologic Response Modifiers in Pediatric Rheumatology. , 2017, , 77-87.		0